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Zusammenfassung
Der humanisierte monoklonale Antikörper Pertuzumab ver-
hindert die Dimerisierung von HER2 mit anderen HER- 
Rezep toren, insbesondere die Bildung des im Hinblick auf 
Signal transduktionskaskaden potentesten Heterodimers 
HER2-HER3 und ermöglicht damit eine grundlegend andere 
Strategie der dualen HER2-Inhibition. Pertuzumab bindet an 
die extrazelluläre Domäne von HER2, aber einem anderen 
Epitop als Trastuzumab. Pertuzumab und Trastuzumab er-
reichen zusammen eine vollständigere Blockade der HER2-
vermittelten Signaltransduktion als jede Substanz alleine. 
Phase-II-Studien konnten zeigen, dass Pertuzumab alleine 
oder in Kombination gut verträglich ist. Sie legten auch eine 
verbesserte klinische Wirksamkeit der Kombination von Per-
tuzumab und Trastuzumab bei primärem und fortgeschritte-
nem HER2-positiven Brustkrebs nahe. Die Ergebnisse der 
Phase-III-Studie CLEOPATRA bei Patientinnen mit metasta-
siertem HER2-positivem Mammakarzinom zeigten, dass die 
zusätzliche Gabe von Pertuzumab zu einer Erstlinien-Kombi-
nationstherapie mit Docetaxel und Trastuzumab das pro-
gressionsfreie Überleben und das Gesamtüberleben signifi-
kant verlängerte ohne Steigerung der kardialen Toxizität. 
Derzeit wird die Kombination aus beiden Antikörpern in der 
palliativen Situation und in der Behandlung des frühen 
HER2-positiven Mammakarzinoms untersucht. Die duale 
HER2-Inhibition mit Trastuzumab und dem HER2 Dimerisati-
onsinhibitor Pertuzumab könnte die klinische Praxis für die 
Erstlinientherapie beim metastasierten HER2-positiven 
Mammakarzinom und möglicherweise auch in früheren Sta-
dien verändern. 
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Summary
The humanized monoclonal antibody pertuzumab prevents 
the dimerization of HER2 with other HER receptors, in par-
ticular the pairing of the most potent signaling heterodimer 
HER2/HER3, thus providing a potent strategy for dual HER2 
inhibition. It binds to the extracellular domain of HER2 at a 
different epitope than trastuzumab. Pertuzumab and trastu-
zumab act in a complementary fashion and provide a more 
complete blockade of HER2-mediated signal transduction 
than either agent alone. Phase II studies demonstrated that 
pertuzumab was generally well tolerated as a single agent 
or in combination with trastuzumab and/or cytotoxic agents, 
and implied an improved clinical efficacy of the combina-
tion of pertuzumab and trastuzumab in early and advanced 
HER2-positive breast cancer. Results of the pivotal phase III 
study CLEOPATRA in patients with HER2-positive metastatic 
breast cancer demonstrated that the addition of pertuzumab 
to first-line combination therapy with docetaxel and trastu-
zumab significantly prolonged progression-free and overall 
survival without increasing cardiac toxicity. Currently, the 
combination of both antibodies is being explored in the 
 palliative setting as well as in the treatment of early HER2-
positive breast cancer. Dual HER2 inhibition with the HER2 
dimerization inhibitor pertuzumab and trastuzumab may 
change clinical practice in HER2-positive first-line metastatic 
breast cancer treatment.
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Introduction
According to a current analysis of more than 18,000 results of 
HER2 testing in clinical routine practice, 16.7 ± 3.2% (95% 
confidence interval (CI) 16.6–16.8) of patients with early 
breast cancer have HER2-positive tumors [1]. HER2 positiv-
ity is correlated with aggressive breast tumor behavior and 
 associated with reduced response to standard therapies and 
decreased breast cancer survival [2, 3]. The introduction of 
targeted therapy against HER2 has significantly changed the 
prognosis of patients with HER2-positive breast cancer, trans-
forming HER2 positivity from a negative prognostic to a 
 positive predictive disease marker. Trastuzumab has become 
the standard of care that significantly improves outcomes in 
patients with HER2-positive early breast cancer [4–9] and 
HER2-positive metastatic breast cancer (MBC) [10, 11]. Yet, 
despite the proven efficacy of trastuzumab plus chemo-
therapy, some patients with HER2-positive breast cancer do 
not respond, and the disease in the majority of patients with 
MBC progresses within 1 year. The medical need for targeted 
therapy for advanced disease is being addressed through in-
tensive research efforts. Dual therapy targeting HER2 has 
been identified as a promising treatment strategy [12]. The 
humanized monoclonal antibody pertuzumab binds to the 
 extracellular domain of HER2. It prevents the dimerization of 
HER2 with other HER receptors, especially HER3 [13] and 
allows for a fundamentally different strategy of dual HER2 
inhibition. 
HER Family and HER2-HER3 Heterodimer
The 4 type 1 transmembrane tyrosine kinase receptors EGFR 
(or HER1), HER2, HER3 and HER4 constitute the HER 
family. HER1, HER2 and HER3 are all implicated in the 
 development and progression of cancer [14]. In principle, each 
receptor consists of an extracellular domain that binds  ligands, 
a transmembrane region and a cytoplasmic domain with 
 kinase activity, with the exceptions that there is no known 
 ligand to HER2, and HER3 does not exert tyrosine kinase 
 activity. Ligand binding induces conformational rearrange-
ments of the receptors, and promotes association of both 
 homodimers and heterodimers. This is followed by internali-
zation, phosphorylation and further downstream signaling, 
thus regulating many cellular processes including cell growth, 
proliferation and survival [15]. 
Not all of the 10 possible dimers are fully biologically 
 active. HER2 and HER3 are highly complementary to each 
other: HER3 binds ligand yet lacks intrinsic kinase activity; 
HER2 has intrinsic tyrosine kinase activity but no identified 
ligand [14]. The HER2/HER3 heterodimer is considered the 
most potent HER dimer pair with respect to strength of inter-
action, ligand-induced tyrosine phosphorylation and down-
stream signaling [16, 17]. In vitro, reduction of HER3 expres-
sion decreased cell proliferation to the same extent as reduc-
tion of HER2 expression [18]. Also, HER3 provides an  escape 
route for breast cancer when HER1 and HER2 are inhibited 
by tyrosine kinase inhibitors [19, 20].
Pertuzumab – Mode of Action and Rationale  
for Combination with Trastuzumab
Pertuzumab is a humanized monoclonal antibody that binds 
to the dimerization domain of HER2. Blocking the pairing of 
the most potent signaling HER dimer, HER2-HER3, affects 
key signaling pathways [13, 17, 20, 21]. As it binds to the 
 extracellular domain of HER2 pertuzumab can also activate 
immune effector functions such as antibody-dependent cell-
mediated cytotoxicity [22].
In vitro studies have shown that trastuzumab and pertu-
zumab bind to different epitopes on the HER2 protein [13]. 
Concomitant binding of both antibodies has also been demon-
strated in vivo [22]. The modes of action of trastuzumab 
and pertuzumab are complementary (fig. 1). Trastuzumab 
 inhibits ligand-independent HER2 signaling, prevents HER2 
activation by extracellular domain shedding, and flags cells 
for  destruction by the immune system [22–24]; however, it 
cannot prevent ligand-activated HER2/HER3 or HER2/
HER1 hetero dimerization, a potential escape mechanism for 
tumor cells from the inhibitory effects of trastuzumab [13, 21, 
25]. There is preclinical evidence for the synergy of trastu-
zumab and pertuzumab in HER2-overexpressing tumors and 
 spe cifically in HER2-overexpressing breast cancer. It was 
 demonstrated that trastuzumab and pertuzumab synergisti-
cally inhibited the survival of HER2-overexpressing BT474 
breast cancer cells in vitro [24]. In vivo, the combination of 
trastuzumab and pertuzumab dramatically enhanced the anti-
tumor effect in an HER2-overexpressing breast cancer xeno-
graft model compared to each antibody as a single agent [22]. 
Fig. 1. Complementary mechanisms of action of pertuzumab and 
trastuzumab. Adapted from Baselga J et al. [40] 
ADCC = antibody-dependent cell-mediated cytotoxicity;  
ECD = extracellular domain.
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In addition, the combination of pertuzumab and trastuzumab 
was effective following progression on trastuzumab [22].
Clinical Data
Monotherapy with Pertuzumab
Single-agent pertuzumab has been evaluated in 2 phase I 
studies in 39 patients with solid tumors. The results demon-
strated that pertuzumab was well tolerated and had a pharma-
cokinetic profile supporting 3-week dosing [26]. The maxi-
mum tolerated dose (MTD) was not reached up to the dose 
level of 25 mg/kg [27]. Results also implied potential flat 
dosing. 
Five phase II studies in unselected patients with advanced 
prostate, non-small cell, ovarian and breast cancer demon-
strated a modest clinical activity of single-agent pertuzumab 
[28–32]. Pertuzumab was generally well tolerated. Most 
 adverse events were grade 1–2. Diarrhea, rash, asthenia, 
 vomiting, nausea and abdominal pain were most common. A 
pooled analysis of 598 patients from 14 studies with pertu-
zumab as a single agent, or in combination with capecitabine, 
docetaxel, gemcitabine, carboplatin, paclitaxel, erlotinib or 
trastuzumab showed an at least similar cardiac safety as 
trastuzumab. 23 of 331 patients across all studies with single-
agent pertuzumab developed asymptomatic left ventricular 
systolic dysfunction and 1 (0.3%) symptomatic heart failure 
[33]. There was no notable increase in cardiac side effects 
when pertuzumab was given in combination with non-anthra-
cycline cytotoxics, erlotinib or trastuzumab.
A phase II study performed in 79 patients with HER2- 
negative breast cancer evaluated pertuzumab given once 
every 3 weeks with a loading dose of 840 mg followed by 
 either 420 mg or 1,050 mg. Pharmacokinetic data supported 
a fixed dose of pertuzumab once every 3 weeks [32]. Analysis 
of pooled data from 153 patients from 3 clinical studies in 
which pertuzumab was either administered every 3 weeks as a 
weight-based or fixed dose (420 or 1,050 mg) indicated that 
pharmacokinetic profiles were similar, thus proving the feasi-
bility of administering pertuzumab as a fixed dose [34].
Dual HER2 Inhibition with Pertuzumab and Trastuzumab – 
Phase II Studies
A phase II study in patients with HER2-positive MBC with 
progression during prior trastuzumab therapy provided the 
first evidence that the combination of the 2 antibodies pertu-
zumab and trastuzumab, without additional chemotherapy, 
was clinically active and well tolerated [35]. The overall re-
sponse rate for the 66 patients treated with the combination of 
both antibodies was 24.2%. Complete response (CR) was 
seen in 4 (6.1%), partial response (PR) in 12 (18.2%), and 
 stable disease (SD) for 6 months in 17 (25.8%) patients. 
 Median progression-free survival (PFS) was 5.5 months. 
 Adverse events were generally grade 1 or 2 and included 
 diarrhea, fatigue, nausea, and rash. 4 patients experienced 
treatment-related adverse events of grade 3 or higher. There 
were no significant cardiac events. Only 3 patients had a 
 decrease in left ventricular ejection fraction (LVEF) of > 10% 
points from baseline or to < 50% of the absolute value. No 
patient withdrew due to cardiac-related adverse events [35].
Data for the efficacy and safety of the combination of per-
tuzumab and trastuzumab also come from 2 large randomized 
studies in the neoadjuvant setting. 417 patients with locally 
advanced, inflammatory or early HER2-positive breast cancer 
were enrolled in the international randomized phase II trial 
NeoSphere [36]. Patients were randomized into 4 arms and 
 received trastuzumab plus docetaxel in arm A, pertuzumab, 
trastuzumab plus docetaxel in arm B, pertuzumab and trastu-
zumab in arm C and pertuzumab plus docetaxel in arm D. 
Study drugs were given every 3 weeks for 4 cycles before sur-
gery. Trastuzumab was given with a loading dose of 8 mg/kg 
and at 6 mg/kg subsequently, pertuzumab at a loading dose of 
840 mg and then at 420 mg, and docetaxel at 75 mg/m2 escalat-
ing if tolerated to 100 mg/m2. The highest pathological CR 
(pCR) of 45.8% was achieved with the combination of pertu-
zumab, trastuzumab plus docetaxel as compared to 29% for 
trastuzumab plus docetaxel (p = 0.0141) and 24.0% with per-
tuzumab plus docetaxel (p = 0.003). Of note, patients treated 
with the chemotherapy-free combination of pertuzumab and 
trastuzumab had a pCR of 16.8%. Fewer pCRs were seen in 
hormone receptor-positive tumors across all study arms. The 
most frequent adverse events were mostly grade 1–2 and were 
alopecia, neutropenia, diarrhea, nausea, fatigue rash and 
 mucosal inflammation. The lowest incidence of adverse events 
≥ grade 3 was recorded for the combination of pertuzumab 
and trastuzumab. The mean maximum decrease in LVEF 
was low (4–5%) and balanced across treatment arms. Adding 
pertuzumab to trastuzumab did not result in an increase of 
cardiac toxicity [36]. Extensive biomarker analyses have been 
performed but so far have not yielded clinically useful assays 
for patient or regimen selection in addition or alternatively to 
conventional HER2 assessment used at present [37].
Another 223 patients with HER2-positive locally  advanced, 
inflammatory or early stage breast cancer were assigned to 3 
arms of 6 cycles of neoadjuvant treatment in the TRYPHAENA 
study, an international randomized phase II study [38]. Pa-
tients in arm A received FEC (5-flurouracil, epi rubicin, cyclo-
phosphamide) in cycles 1–3 and docetaxel in  cycles 4–6 plus 
pertuzumab and trastuzumab from cycles 1–6. Patients in arm 
B were treated with FEC from cycles 1–3 and docetaxel from 
cycles 4–6 plus pertuzumab and trastuzumab from cycles 4–6 
only. In arm C, patients received docetaxel and carboplatin 
plus pertuzumab and trastuzumab from cycles 1–6. Study 
drugs were administered every 3 weeks. Pertuzumab was 
given at a loading dose of 840 mg and at 420 mg subsequently, 
and trastuzumab at a loading dose of 8 mg/kg and at 6 mg/kg 
subsequently. Following surgery, patients received trastu-
zumab to complete 1 year of treatment. The primary endpoint 
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group. Median duration of study treatment was 11.8 and 
18.1 months, respectively. A median of 8 cycles of docetaxel 
were administered in both groups. 
The primary endpoint of independently assessed PFS was 
met. Pertuzumab increased PFS by 6.1 months from 
12.4 months in the control group to 18.5 months in the experi-
mental arm (fig. 3). The treatment benefit was consistent 
across all prespecified subgroups except for the subgroup of 
patients with non-visceral disease. In particular, there was a 
clear treatment benefit in both hormone receptor-negative 
and -positive patients. In the 288 patients who had received 
adjuvant or neoadjuvant therapy without trastuzumab, inde-
pendently assessed PFS was 12.6 months for the control and 
21.6 months for the pertuzumab group (hazard ratio (HR) = 
0.60; 95% CI, 0.43–0.83). For the 88 patients with prior neoad-
juvant or adjuvant trastuzumab, median independently as-
sessed PFS was 10.4 and 16.9 months (HR = 0.62; 95% CI, 
0.35–1.07), respectively.
Analysis of the secondary endpoint, overall survival, is 
event-driven. A preplanned interim analysis performed after 
165 events and a median follow-up of 19.3 months showed a 
of the study was cardiac safety, assessed by a thorough follow-
up of 15 LVEF assessments up to 60 months post randomiza-
tion. Cardiac toxicity was generally mild in all treatment arms 
with symptomatic left ventricular systolic  dysfunction (LVSD) 
≥ grade 3 in 0%, 2.7% and 0%, and LVEF decline ≥ 10% 
points from baseline or to < 50% in 4.2%, 5.3% and 3.9% of 
patients for arms A, B, and C,  respectively. There was no dif-
ference in cardiac side effects for concurrent administration of 
pertuzumab plus trastuzumab with epirubicin compared with 
sequential administration or the anthracycline-free regimen. 
Neutropenia, febrile neutropenia, leukopenia, and diarrhea 
were most frequently reported adverse events of ≥ grade 3 
across all arms. Regardless of chemotherapy chosen, the com-
bination of pertuzumab with trastuzumab in the neoadjuvant 
setting resulted in high pCR rates of 61.6%, 57.3% and 66.2% 
for arms A, B, and C, respectively [38].
Dual HER2 Inhibition with Pertuzumab and Trastuzumab – 
Pivotal Phase III Study in First-line MBC Treatment
In the pivotal phase III trial CLEOPATRA, 808 patients 
with centrally confirmed HER2-positive locally recurrent, 
 unresectable, or metastatic breast cancer were randomized 
[39, 40]. For inclusion, patients could have had only a prior 
hormonal regimen for MBC. Prior neoadjuvant or adjuvant 
systemic therapy, including trastuzumab and/or taxanes, was 
allowed if the disease-free interval was ≥ 12 months. Patients 
were treated until the time of disease progression or the de-
velopment of unacceptable toxicity either with a combination 
of docetaxel, trastuzumab and placebo in the control group or 
docetaxel, trastuzumab and pertuzumab in the experimental 
arm (fig. 2). The recommendation was to administer at least 
6 cycles of chemotherapy. If chemotherapy was discontinued 
due to toxicity, antibody therapy could be continued until 
 disease progression or onset of unacceptable toxicity. 75% of 
all patients discontinued docetaxel but continued to receive 
pertuzumab or placebo plus trastuzumab treatment. The 
 median number of treatment cycles per patient was 15 (range 
1–50) in the control and 18 (range 1–56) in the pertuzumab 
Fig. 2. CLEOPATRA: Study design. Adapted from Baselga J et al. [40]. 
MBC = metastatic breast cancer; PD = progressive disease.
Fig. 3. Independently and investigator-assessed progression-free survival. 
Adapted from Baselga J et al. [39, 40].
Fig. 4. CLEOPATRA: Predefined interim analysis of overall survival 
(n=165 events). Adapted from Baselga J et al. [39, 40]. 
D = docetaxel; OS = overall survival; Pla = placebo; Ptz = pertuzumab;  
T = trastuzumab.
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strong trend toward a survival benefit with pertuzumab-
trastuzumab-docetaxel with an HR of 0.64 (95% CI, 0.47–
0.88) (fig. 4). The confirmatory overall survival analysis 
 performed after 267 deaths and a median follow-up of 
30 months in both arms confirmed a significant survival 
 benefit for the combination of pertuzumab, trastuzumab and 
docetaxel (HR = 0.66; 95% CI, 0.52–0.84, p = 0.0008) [41]. 
There was also a significant increase in objective response 
rate from 69.3% in the control to 80.2% in the pertuzumab 
group (p = 0.001).
The combination of pertuzumab and trastuzumab plus 
docetaxel increased rates of diarrhea, rash, mucosal inflam-
mation, febrile neutropenia, and dry skin. These adverse 
events were primarily grades 1 or 2 and manageable [39, 40]. 
The great majority of events (all grades and grades ≥ 3) oc-
curred during concomitant antibody and docetaxel adminis-
tration with a substantial reduction in rates of the most com-
mon adverse events following discontinuation of docetaxel. 
After stopping administration of docetaxel febrile neutrope-
nia was no longer reported in the placebo or the pertuzumab 
arm [42]. Importantly, there was no increase in cardiac ad-
verse events or LVSD with the addition of pertuzumab 
(table 1). A univariate Cox regression analysis demonstrated 
that development of LVSD was associated with prior therapy 
with anthracyclines and prior radiotherapy. There was no 
 significant association between prior trastuzumab therapy and 
development of LVSD [43].
Quality of life was similar for both study arms. An explor-
atory analysis showed that the combination of pertuzumab, 
trastuzumab and docetaxel was associated with a substantial 
delay in the time to onset of specific breast cancer symptoms 
with a median time to deterioration of symptoms of 
18.3 weeks for placebo, trastuzumab and docetaxel compared 
to 26.7 weeks for the pertuzumab, trastuzumab and docetaxel 
arm (HR = 0.77; 95% CI 0.64–0.93, p = 0.0061) [44].
Pertuzumab – Ongoing and Planned Studies
There are a number of ongoing and planned studies aimed at 
evaluating the combination of pertuzumab and trastuzumab 
in different settings of HER2-positive breast cancer. The on-
going randomized phase II study PHEREXA is evaluating 
the efficacy and safety of trastuzumab plus capecitabine with 
or without the addition of pertuzumab in the treatment of 
 patients with HER2-positive MBC who progressed after 1 line 
of trastuzumab-based therapy. The planned randomized 
phase II study VELVET will evaluate how the addition of 
pertuzumab affects efficacy and safety of the combination of 
trastuzumab and vinorelbine as a first- or second-line treat-
ment of patients with HER2-positive MBC. 
The German Breast Group started the randomized phase 
III trial, GEPARSepto, comparing neoadjuvant paclitaxel 
to nano particle albumin-bound (nab)-paclitaxel and evaluat-
ing dual inhibition with trastuzumab plus pertuzumab in 
HER2-positive patients. Moreover, surrogate markers for 
early response to dual inhibition with trastuzumab and pertu-
zumab will also be evaluated in the WSG ADAPT Trial 
(www.wsg-online.com). Finally, the large international phase 
III study APHINITY (fig. 5) will evaluate the added value of 
pertuzumab for the adjuvant treatment of patients with 
HER2-positive early breast cancer. In this trial, following an 
upfront physicians’ choice between an anthracycline-based 
and a non-anthracycline platinum-based adjuvant chemo-
therapy regimen, patients will be randomized to standard ad-
juvant trastuzumab plus pertuzumab or adjuvant trastuzumab 
plus placebo.
Table 1. CLEOPATRA: Cardiac tolerabilitya
Placebo + trastuzumab + docetaxel Pertuzumab + trastuzumab + docetaxel
n 397 407
Investigator-assessed symptomatic LVSDb 1.8% 1.0% 
Independently adjudicated symptomatic LVSDb 1.0% 1.0% 
Fall in LVEF to < 50% or by ≥ 10% points from baseline 6.6% 3.8% 
LVEF = left ventricular ejection fraction, LVSD = left ventricular systolic dysfunction.
aAdapted from Baselga J et al. [40].
bSymptomatic LVSD was defined as New York Heart Association (NYHA) class III/IV.
Fig. 5. APHINITY: Study design. Trastuzumab loading dose at first cycle 
8 mg/kg, dose of 6 mg/kg 3-weekly in subsequent cycles. Pertuzumab 
loading dose of 840 mg i.v., dose of 420 mg i.v. 3-weekly in subsequent 
cycles. Placebo i.v. 3 weekly. A limited number of standard anthracycline 
or non-anthracycline (TCH) regimens are allowed.
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Conclusions
Due to their different mechanisms of action, pertuzumab and 
trastuzumab act in a complementary fashion and provide a 
more complete blockade of HER2-mediated signal transduc-
tion than either agent alone. Proof of principle of the efficacy 
of dual HER2 inhibition with the dimerization inhibitor per-
tuzumab and trastuzumab has been provided by the data of 
the pivotal phase III study CLEOPATRA, which has shown a 
significant and clinically relevant prolongation of PFS by 
6.1 months with the addition of pertuzumab in first-line 
HER2-positive MBC, resulting in a significant survival bene-
fit. Most importantly, several studies demonstrated that add-
ing pertuzumab is not associated with increased cardiac toxic-
ity. Currently, the combination of both antibodies is being ex-
plored in the palliative setting as well as in the treatment of 
early HER2-positive breast cancer. Dual HER2 inhibition 
with pertuzumab and trastuzumab may change clinical prac-
tice in HER2-positive first-line MBC, and beyond, in HER2-
positive breast cancer.
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